Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study
- PMID: 19192441
- DOI: 10.4088/jcp.v69n1008
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study
Abstract
Objective: The objective of this study was to compare the 3-year course of schizophrenia between persons with tardive dyskinesia (TD) and persons without TD on multiple outcome measures.
Method: Data were drawn from a large, prospective, naturalistic study of persons treated for schizophrenia-spectrum disorders (DSM-IV criteria) in the United States, conducted between July 1997 and September 2003. Treatment outcomes were assessed at enrollment and at 12, 24, and 36 months postenrollment using measures of symptoms, functioning, productivity, activity, and quality of life. Participants who had TD at enrollment (fulfilling Schooler-Kane criteria, N = 637) were compared with those who did not (N = 1538) on clinical and functional measures at enrollment and across the 3 years of follow-up. Additional analyses examined those with persistent TD compared to those without persistent TD.
Results: With adjustment for known correlates of TD, participants with TD compared to those without TD had significantly more severe psychopathology, were less likely to experience symptom remission, had more severe extrapyramidal side effects, and had lower levels of quality of life and functioning, lower productivity, and fewer activities (all p < .001) across the 3-year follow-up. Findings were essentially unchanged when the subgroup of participants with persistent TD (at enrollment and at 1 year) was examined.
Conclusion: These results indicate that, in the long-term treatment of schizophrenia, persons with TD have a significantly more severe and more refractory course of illness than those without TD, suggesting poorer prognosis and the need for specialized interventions.
Copyright 2008 Physicians Postgraduate Press, Inc.
Similar articles
-
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.Schizophr Res. 2005 Sep 15;77(2-3):129-39. doi: 10.1016/j.schres.2005.03.015. Schizophr Res. 2005. PMID: 15913962 Clinical Trial.
-
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.Schizophr Res. 2005 Dec 1;80(1):33-43. doi: 10.1016/j.schres.2005.07.034. Epub 2005 Sep 19. Schizophr Res. 2005. PMID: 16171976 Clinical Trial.
-
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.Eur Arch Psychiatry Clin Neurosci. 2004 Dec;254(6):356-61. doi: 10.1007/s00406-004-0514-1. Epub 2004 Nov 12. Eur Arch Psychiatry Clin Neurosci. 2004. PMID: 15538607 Clinical Trial.
-
Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S76-80. Can J Psychiatry. 1994. PMID: 7874668 Review.
-
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?Mov Disord. 2006 May;21(5):589-98. doi: 10.1002/mds.20823. Mov Disord. 2006. PMID: 16532448 Review.
Cited by
-
Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study.J Am Psychiatr Nurses Assoc. 2023 Sep-Oct;29(5):389-399. doi: 10.1177/10783903211023565. Epub 2021 Jun 22. J Am Psychiatr Nurses Assoc. 2023. PMID: 34154444 Free PMC article.
-
Cholinergic medication for antipsychotic-induced tardive dyskinesia.Cochrane Database Syst Rev. 2018 Mar 19;3(3):CD000207. doi: 10.1002/14651858.CD000207.pub2. Cochrane Database Syst Rev. 2018. PMID: 29553158 Free PMC article.
-
Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.Cochrane Database Syst Rev. 2015 Apr 13;2015(4):CD010501. doi: 10.1002/14651858.CD010501.pub2. Cochrane Database Syst Rev. 2015. PMID: 25866243 Free PMC article.
-
Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.J Child Adolesc Psychopharmacol. 2013 Dec;23(10):665-75. doi: 10.1089/cap.2013.0007. Epub 2013 Nov 22. J Child Adolesc Psychopharmacol. 2013. PMID: 24266529 Free PMC article.
-
Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.PLoS One. 2013 Aug 15;8(8):e71034. doi: 10.1371/journal.pone.0071034. eCollection 2013. PLoS One. 2013. PMID: 23967150 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical